Martin J. Muller

Hohe Str. 6
Dresden, SN 01069, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2026

In-vivo effects of antibacterial polyelectrolyte multilayer coatings functionalized by bacteriophages for metallic medical implants.

In-vivo effects of antibacterial polyelectrolyte multilayer coatings functionalized by bacteriophages for metallic medical implants.

Journal: Biomaterials advances

Published: December 08, 2025

Expedient Access to Gold/Quantum-Dot Nanohybrids Mediated by Poly(ethylene Glycol) Ligands of Distinct Macromolecular Architecture.

Expedient Access to Gold/Quantum-Dot Nanohybrids Mediated by Poly(ethylene Glycol) Ligands of Distinct Macromolecular Architecture.

Journal: Macromolecular rapid communications

Published: August 12, 2025

Gold Nanorods Decorated by Conjugated Microporous Polymers for Infrared Responsive Cytostatic Drug Delivery.

Gold Nanorods Decorated by Conjugated Microporous Polymers for Infrared Responsive Cytostatic Drug Delivery.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: January 23, 2025

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2024

Determination of the pKa Value of Protonated Mono and Polyamine in Solution Using Fourier Transform Infrared Titration.

Determination of the pKa Value of Protonated Mono and Polyamine in Solution Using Fourier Transform Infrared Titration.

Journal: Applied spectroscopy

Published: December 20, 2023

Swelling and Orientation Behavior of End-Grafted Polymer Chains by In Situ Attenuated Total Reflection Fourier Transform Infrared Spectroscopy Complementing In Situ Ellipsometry.

Swelling and Orientation Behavior of End-Grafted Polymer Chains by In Situ Attenuated Total Reflection Fourier Transform Infrared Spectroscopy Complementing In Situ Ellipsometry.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: November 09, 2023

Advancing Antiamyloidogenic Activity by Fine-Tuning Macromolecular Topology.

Advancing Antiamyloidogenic Activity by Fine-Tuning Macromolecular Topology.

Journal: Biomacromolecules

Published: November 08, 2023

Influence of the Sequence Motive Repeating Number on Protein Folding in Spider Silk Protein Films.

Influence of the Sequence Motive Repeating Number on Protein Folding in Spider Silk Protein Films.

Journal: Biomacromolecules

Published: November 07, 2023

β-Sheet Structure Formation within Binary Blends of Two Spider Silk Related Peptides.

β-Sheet Structure Formation within Binary Blends of Two Spider Silk Related Peptides.

Journal: Biomacromolecules

Published: January 12, 2023

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: June 11, 2022

Showing 1-12 of 48

Last Updated: 09/26/2026